Physician profile
Anil Jasti
NPI 1669433009
$724.14
in general payments reported to CMS, 2019-2025
14 companies · $506 in 2025
The $506 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.06 · 2022: $22.05 · 2023: $76.02 · 2024: $53.77 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $576.04 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $193.45 | 2019-2025 | Otezla, Evenity, Repatha |
| Corcept Therapeutics | $65.86 | 2024-2025 | Korlym |
| Actelion Pharmaceuticals US, INC. | $59.99 | 2023 | Uptravi, Opsumit |
| Abbvie INC. | $57.58 | 2025 | |
| Lilly USA, LLC | $54.47 | 2025 | Jardiance, Zepbound, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.03 | 2025 | Xifaxan |
| Ucb, INC. | $43.47 | 2025 | Cimzia, Bimzelx |
| Novo Nordisk INC | $41.88 | 2025 | Ozempic |
| Glaxosmithkline, LLC. | $38.84 | 2019 | |
| Recordati_rare_diseases_inc. | $36.76 | 2025 | Isturisa |
| Axsome Therapeutics, INC. | $25.76 | 2025 | Auvelity |
| Janssen Biotech, INC. | $22.05 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $19.38 | 2024 | Airsupra |
| Phathom Pharmaceuticals, INC. | $18.62 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Jasti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.